UnitedHealth Forecast, price target & analysts
UnitedHealth Target price 2025 - Analyst rating & recommendation
UnitedHealth Classifications & Recommendation:
UnitedHealth Price Target
| Target Price | $565.17 |
| Price | $424.25 |
| Potential | 33.22% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target UnitedHealth 2026 . The average UnitedHealth target price is $565.17. This is 33.22% higher than the current stock price. The highest price target is $677.00 59.58% , the lowest is $490.00 15.50% . | |
| A rating was issued by 30 analysts: 27 Analysts recommend UnitedHealth to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the UnitedHealth stock has an average upside potential 2026 of 33.22% . Most analysts recommend the UnitedHealth stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
21 Analysts have issued a sales forecast UnitedHealth 2025 . The average UnitedHealth sales estimate is $451b . This is 10.05% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $458b 11.76% , the lowest is $444b 8.37% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $400b | 8.83% |
|---|---|---|
| 2025 | $451b | 12.74% |
| 2026 | $486b | 7.75% |
| 2027 | $522b | 7.30% |
| 2028 | $569b | 9.03% |
| 2029 | $613b | 7.75% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
14 Analysts have issued a UnitedHealth forecast for earnings per share. The average UnitedHealth EPS is $24.88 . This is 4.01% higher than earnings per share in the financial year 2024. The highest EPS forecast is $26.20 9.53% , the lowest is $24.60 2.84% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $15.51 | 35.00% |
|---|---|---|
| 2025 | $24.88 | 60.41% |
| 2026 | $29.00 | 16.56% |
| 2027 | $33.31 | 14.86% |
| 2028 | $39.06 | 17.26% |
| 2029 | $44.40 | 13.67% |
P/E ratio
| Current | 17.73 | 42.08% |
|---|---|---|
| 2025 | 17.05 | 3.84% |
| 2026 | 14.63 | 14.19% |
| 2027 | 12.74 | 12.92% |
| 2028 | 10.86 | 14.76% |
| 2029 | 9.55 | 12.06% |
Based on analysts' sales estimates for 2025, the UnitedHealth stock is valued at an EV/Sales of 0.97 and an P/S ratio of 0.86 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.07 | 21.32% |
|---|---|---|
| 2025 | 0.97 | 9.00% |
| 2026 | 0.90 | 7.20% |
| 2027 | 0.84 | 6.80% |
| 2028 | 0.77 | 8.29% |
| 2029 | 0.72 | 7.19% |
P/S ratio
| Current | 0.95 | 22.27% |
|---|---|---|
| 2025 | 0.86 | 9.14% |
| 2026 | 0.80 | 7.19% |
| 2027 | 0.74 | 6.80% |
| 2028 | 0.68 | 8.28% |
| 2029 | 0.63 | 7.20% |
Current UnitedHealth Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Apr 24 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
| HSBC |
Buy
➜
Hold
|
Downgrade | Apr 22 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Apr 22 2025 |
| Argus Research |
Buy
➜
Hold
|
Downgrade | Apr 21 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 21 2025 |
| Keybanc |
Overweight
➜
Overweight
|
Unchanged | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Apr 24 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 23 2025 |
|
Downgrade
HSBC:
Buy
➜
Hold
|
Apr 22 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Apr 22 2025 |
|
Downgrade
Argus Research:
Buy
➜
Hold
|
Apr 21 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 21 2025 |
|
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Apr 21 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
